Exact Mass: 395.2460308000001

Exact Mass Matches: 395.2460308000001

Found 253 metabolites which its exact mass value is equals to given mass value 395.2460308000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

benzyl cetraxate

Cetraxate benzyl ester

C24H29NO4 (395.20964740000005)


The benzyl ester of cetraxate.

   

4-Hydroxy-2-methyl-3-oxo-4-farnesyl-3,4-dihydroquinoline-1-oxide

4-Hydroxy-2-methyl-3-oxo-4-[(2E,6E)-farnesyl]-3,4-dihydroquinoline 1-oxide

C25H33NO3 (395.2460308000001)


A member of the class of quinoline N-oxides that is 4-hydroxy-2-methyl-3-oxo-3,4-dihydroquinoline-1-oxide carrying an additional (2E,6E)-farnesyl group at position 4.

   
   

(2R,5E)-6,10-dimethyl-2-[(2S)-4-methyl-5-oxido-1,2-dihydrofuro[2,3-c]quinolin-5-ium-2-yl]undeca-5,9-dien-2-ol

(2R,5E)-6,10-dimethyl-2-[(2S)-4-methyl-5-oxido-1,2-dihydrofuro[2,3-c]quinolin-5-ium-2-yl]undeca-5,9-dien-2-ol

C25H33NO3 (395.2460308000001)


   
   

Prostaglandin E2 ethanolamide

(5Z)-7-[(1R,2R,3S)-3-Hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]-N-(2-hydroxyethyl)hept-5-enimidate

C22H37NO5 (395.26715920000004)


prostaglandin E2 ethanolamide is the major prostanoid product derived from anandamide. Incubation of anandamide with lysates and the intact cell line expressing COX-2 but not that of COX-1 produced prostaglandin E2 ethanolamide. This reaction demonstrates the existence of a COX-2-mediated pathway for anandamide metabolism, and the metabolites formed represent a novel class of prostaglandins. Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. prostaglandin E2 ethanolamide is the major prostanoid product derived from anandamide. Incubation of anandamide with lysates and the intact cell line expressing COX-2 but not that of COX-1 produced prostaglandin E2 ethanolamide. This reaction demonstrates the existence of a COX-2-mediated pathway for anandamide metabolism, and the metabolites formed represent a novel class of prostaglandins.

   

PGD2 ethanolamide

(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]-N-(2-hydroxyethyl)hept-5-enamide

C22H37NO5 (395.26715920000004)


PGD2 ethanolamide is a N-acylethanolamine. N-acylethanolamines (NAEs) constitute a class of lipid compounds naturally present in both animal and plant membranes as constituents of the membrane-bound phospholipid, N-acylphosphatidylethanolamine (NAPE). NAPE is composed of a third fatty acid moiety linked to the amino head group of the commonly occurring membrane phospholipid, phosphatidylethanolamine. NAEs are released from NAPE by phospholipase D-type hydrolases in response to a variety of stimuli. Transient NAE release and accumulation has been attributed a variety of biological activities, including neurotransmission, membrane protection, and immunomodulation in animals. N-oleoylethanolamine is an inhibitor of the sphingolipid signaling pathway, via specific ceramidase inhibition (ceramidase converts ceramide to sphingosine). N-oleoylethanolamine blocks the effects of TNF- and arachidonic acid on intracellular Ca concentration. (PMID: 12692337, 12056855, 12560208, 11997249) [HMDB] PGD2 ethanolamide is a N-acylethanolamine. N-acylethanolamines (NAEs) constitute a class of lipid compounds naturally present in both animal and plant membranes as constituents of the membrane-bound phospholipid, N-acylphosphatidylethanolamine (NAPE). NAPE is composed of a third fatty acid moiety linked to the amino head group of the commonly occurring membrane phospholipid, phosphatidylethanolamine. NAEs are released from NAPE by phospholipase D-type hydrolases in response to a variety of stimuli. Transient NAE release and accumulation has been attributed a variety of biological activities, including neurotransmission, membrane protection, and immunomodulation in animals. N-oleoylethanolamine is an inhibitor of the sphingolipid signaling pathway, via specific ceramidase inhibition (ceramidase converts ceramide to sphingosine). N-oleoylethanolamine blocks the effects of TNF- and arachidonic acid on intracellular Ca concentration. (PMID: 12692337, 12056855, 12560208, 11997249)

   

Sphingosine 1-phosphate (d19:1-P)

{[(2S,3R)-2-amino-3-hydroxynonadecyl]oxy}phosphonic acid

C19H42NO5P (395.2800452000001)


Sphingosine 1-phosphate (d19:1-P) is a Sphingosine-1-phosphate. Sphingosine-1-phosphate is a signaling sphingolipid. It is also referred to as a bioactive lipid mediator. Sphingolipids at large form a class of lipids characterized by a particular aliphatic aminoalcohol, which is sphingosine. (Wikipedia)

   

Tetradeca-5,8,11-trienedioylcarnitine

3-[(13-carboxytrideca-5,8,11-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


Tetradeca-5,8,11-trienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-5,8,11-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-5,8,11-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-5,8,11-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tetradeca-8,10,12-trienedioylcarnitine

3-[(13-carboxytrideca-8,10,12-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


Tetradeca-8,10,12-trienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-8,10,12-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-8,10,12-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-8,10,12-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tetradeca-5,7,9-trienedioylcarnitine

3-[(13-carboxytrideca-5,7,9-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


Tetradeca-5,7,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-5,7,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-5,7,9-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-5,7,9-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine

3-[(13-carboxytrideca-2,4,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


(2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,4Z,10Z)-tetradeca-2,4,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tetradeca-7,9,11-trienedioylcarnitine

3-[(13-carboxytrideca-7,9,11-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


Tetradeca-7,9,11-trienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-7,9,11-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-7,9,11-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-7,9,11-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tetradeca-6,8,10-trienedioylcarnitine

3-[(13-carboxytrideca-6,8,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


Tetradeca-6,8,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-6,8,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-6,8,10-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-6,8,10-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tetradeca-4,7,10-trienedioylcarnitine

3-[(13-carboxytrideca-4,7,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


Tetradeca-4,7,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-4,7,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-4,7,10-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-4,7,10-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tetradeca-6,9,12-trienedioylcarnitine

3-[(13-carboxytrideca-6,9,12-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H33NO6 (395.23077580000006)


Tetradeca-6,9,12-trienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-6,9,12-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-6,9,12-trienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-6,9,12-trienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-(3-Methyl-5-pentylfuran-2-yl)pentanoylcarnitine

3-{[5-(3-methyl-5-pentylfuran-2-yl)pentanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C22H37NO5 (395.26715920000004)


5-(3-methyl-5-pentylfuran-2-yl)pentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-(3-methyl-5-pentylfuran-2-yl)pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-(3-methyl-5-pentylfuran-2-yl)pentanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-(3-methyl-5-pentylfuran-2-yl)pentanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(3-Methyl-5-propylfuran-2-yl)heptanoylcarnitine

3-{[7-(3-methyl-5-propylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C22H37NO5 (395.26715920000004)


7-(3-Methyl-5-propylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(3-methyl-5-propylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(3-Methyl-5-propylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(3-Methyl-5-propylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide

N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide

C26H37NO2 (395.2824142)


   

Desacetyllevonantradol

6-methyl-3-[(5-phenylpentan-2-yl)oxy]-5,6,6a,7,8,9,10,10a-octahydrophenanthridine-1,9-diol

C25H33NO3 (395.2460308000001)


   

Ethaverine

1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxyisoquinoline

C24H29NO4 (395.20964740000005)


   

Quinagolida

N,N-Diethyl-n-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide hydrochloride, (3alpha,4aalpha,10abeta)-(+)-isomer

C20H33N3O3S (395.22425080000005)


   

spiperone

1-[2-[4-[5-Chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one

C23H26FN3O2 (395.2008948)


   

N-Tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide

N-Tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanimidate

C24H33N3O2 (395.25726380000003)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

   

N-[3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N'-hydroxy-3-(hydroxymethyl)-2-(4-methoxyphenyl)butanediamide

3-(Dihydroxycarbonimidoyl)-N-[2,2-dimethyl-1-(methyl-C-hydroxycarbonimidoyl)propyl]-4-hydroxy-2-(4-methoxyphenyl)butanimidate

C19H29N3O6 (395.20562540000003)


   
   
   
   
   
   

spiperone

spiperone

C23H26FN3O2 (395.2008948)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Spiperone is a potent dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist. Spiperone is a widely used pharmacological tool. Spiperone has the potential for the research of neurology diseases[1].

   
   
   
   

N-(4-hydroxyphenyl)eicosa-5,8,11,14-tetraenamide

N-(4-hydroxyphenyl)eicosa-5,8,11,14-tetraenamide

C26H37NO2 (395.2824142)


   
   
   

N-(4-(3-(3-(3-Aminopropylamino)propylamino)propylamino)butyl)-2,5-dihydroxybenzamide

N-(4-(3-(3-(3-Aminopropylamino)propylamino)propylamino)butyl)-2,5-dihydroxybenzamide

C20H37N5O3 (395.28962520000005)


   

(+)-N-acetyl-N-demethylcyclomicrobuxeine

(+)-N-acetyl-N-demethylcyclomicrobuxeine

C26H37NO2 (395.2824142)


   
   

myceliothermophin E

myceliothermophin E

C26H37NO2 (395.2824142)


   

(E)-(2R,3R,4S)-2-amino-1,3-dihydroxyisooctadec-6-ene-4-sulfate

(E)-(2R,3R,4S)-2-amino-1,3-dihydroxyisooctadec-6-ene-4-sulfate

C18H37NO6S (395.23414620000005)


   

(E)-(2R,3R,4S)-2-amino-1,3-dihydroxyoctadec-6-ene-4-sulfate

(E)-(2R,3R,4S)-2-amino-1,3-dihydroxyoctadec-6-ene-4-sulfate

C18H37NO6S (395.23414620000005)


   
   
   

(S)-Tylohirsuticine|tylohirsuticine

(S)-Tylohirsuticine|tylohirsuticine

C24H29NO4 (395.20964740000005)


   

ethaverine

ethaverine

C24H29NO4 (395.20964740000005)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent C93038 - Cation Channel Blocker

   

N-(3-hydroxyphenyl)icosa-5,8,11,14-tetraenamide

N-(3-hydroxyphenyl)icosa-5,8,11,14-tetraenamide

C26H37NO2 (395.2824142)


   

precondylocarpine acetate

precondylocarpine acetate

C23H27N2O4+ (395.19707220000004)


An organic cation which is an intermediate in the biosynthetic pathway leading to the synthesis of the monoterpenoid indole alkaloids, catharanthine and tabersonine.

   

(2E,4E,12E)-13-(1,3-benzodioxol-5-yl)-1-piperidin-1-yltrideca-2,4,12-trien-1-one

NCGC00385244-01!(2E,4E,12E)-13-(1,3-benzodioxol-5-yl)-1-piperidin-1-yltrideca-2,4,12-trien-1-one

C25H33NO3 (395.2460308000001)


   
   

N-(4-Hydroxyphenyl)arachidonoyl amide

N-(4-Hydroxyphenyl)arachidonoyl amide

C26H37NO2 (395.2824142)


   

Quinagolide

Quinagolide

C20H33N3O3S (395.22425080000005)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

PGD2-EA

N-(9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoyl)-ethanolamine

C22H37NO5 (395.26715920000004)


   

PGE2-EA

(Z)-N-(2-hydroxyethyl)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enamide

C22H37NO5 (395.26715920000004)


   

N-(3-hydroxyphenyl)-Arachidonoyl amide

N-(3-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

C26H37NO2 (395.2824142)


   

AM404

(5Z,8Z,11Z,14Z)-N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide

C26H37NO2 (395.2824142)


   

PGI2-EA

N-(6,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoyl)-ethanolamine

C22H37NO5 (395.26715920000004)


   

PC(O-10:1/0:0)

3,5,9-Trioxa-4-phosphanonadec-18-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)-

C18H38NO6P (395.24366180000004)


   

LPC O-10:1

1-(9E-decenyl)-sn-glycero-3-phosphocholine

C18H38NO6P (395.24366180000004)


   

Sphing-6E-enine 4R-sufate

2S-amino-1,3S-dihydroxyoctadec-6-ene-4R-sulfate

C18H37NO6S (395.23414620000005)


   

2-[(1-Benzylpiperidin-4-yl)hydroxyMethyl]-5,6-dimethoxyindan-1-one

2-[(1-Benzylpiperidin-4-yl)hydroxyMethyl]-5,6-dimethoxyindan-1-one

C24H29NO4 (395.20964740000005)


   

2,6-BIS((DI-TERT-BUTYLPHOSPHINO)METHYL)PYRIDINE

2,6-BIS((DI-TERT-BUTYLPHOSPHINO)METHYL)PYRIDINE

C23H43NP2 (395.2870578)


   

3-Amino-4-chlorobenzoic acid hexadecyl ester

3-Amino-4-chlorobenzoic acid hexadecyl ester

C23H38ClNO2 (395.2590918)


   
   

5,5-dimethyl-8-(3-methyloctan-2-yl)-2-prop-2-ynyl-3,4-dihydro-1H-chromeno[4,3-c]pyridin-10-ol

5,5-dimethyl-8-(3-methyloctan-2-yl)-2-prop-2-ynyl-3,4-dihydro-1H-chromeno[4,3-c]pyridin-10-ol

C26H37NO2 (395.2824142)


   

N,N-BIS(2-HYDROXYETHYL)-N-METHYLTETRADECAN-1-AMINIUM BROMIDE

N,N-BIS(2-HYDROXYETHYL)-N-METHYLTETRADECAN-1-AMINIUM BROMIDE

C19H42BrNO2 (395.23987320000003)


   

rac-(cis/trans) Donepezil N-Oxide

rac-(cis/trans) Donepezil N-Oxide

C24H29NO4 (395.20964740000005)


   

methyl 5-[tert-butyl(dimethyl)silyl]oxy-4-(phenylmethoxycarbonylamino)pentanoate

methyl 5-[tert-butyl(dimethyl)silyl]oxy-4-(phenylmethoxycarbonylamino)pentanoate

C20H33NO5Si (395.21278880000006)


   
   

Benzyl isopropyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate

Benzyl isopropyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate

C23H30BNO4 (395.226777)


   

SR-31747

N-Cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)propen-2-ylamine hydrochloride

C23H35Cl2N (395.21464100000003)


D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D004791 - Enzyme Inhibitors

   

4-(N-BOC-N-phenylamino)phenylboronic acid,pinacol

4-(N-BOC-N-phenylamino)phenylboronic acid,pinacol

C23H30BNO4 (395.226777)


   

6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one

6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one

C20H25N7O2 (395.206963)


   

Gepirone hydrochloride

Gepirone hydrochloride

C19H30ClN5O2 (395.208791)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist

   
   

8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate

8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate

C22H37NO5 (395.26715920000004)


D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

N-[1-(phenylmethyl)-4-piperidinyl]-2-(3-pyridinyl)-4-quinazolinamine

N-[1-(phenylmethyl)-4-piperidinyl]-2-(3-pyridinyl)-4-quinazolinamine

C25H25N5 (395.210985)


   

3-Carboxamido-1,3,5(10)-Estratrien-17(R)-Spiro-2(5,5-Dimethyl-6oxo)tetrahydropyran

3-Carboxamido-1,3,5(10)-Estratrien-17(R)-Spiro-2(5,5-Dimethyl-6oxo)tetrahydropyran

C25H33NO3 (395.2460308000001)


   

6-Phenyl-4(R)-(7-phenyl-heptanoylamino)-hexanoic acid

6-Phenyl-4(R)-(7-phenyl-heptanoylamino)-hexanoic acid

C25H33NO3 (395.2460308000001)


   

1-[2-Hydroxy-3-(4-cyclohexyl-phenoxy)-propyl]-4-(2-pyridyl)-piperazine

1-[2-Hydroxy-3-(4-cyclohexyl-phenoxy)-propyl]-4-(2-pyridyl)-piperazine

C24H33N3O2 (395.25726380000003)


   

4-hydroxy-2-methyl-4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]quinolin-3(4H)-one 1-oxide

4-hydroxy-2-methyl-4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]quinolin-3(4H)-one 1-oxide

C25H33NO3 (395.2460308000001)


   

(2Z,4E,6S,7S,8R,9R,10R)-10-[(1S,3S,4R,5S)-1,4-Dimethyl-2,8-dioxabicyclo[3.2.1]octan-3-yl]-7,9-dihydroxy-2,6,8-trimethylundeca-2,4-dienamide

(2Z,4E,6S,7S,8R,9R,10R)-10-[(1S,3S,4R,5S)-1,4-Dimethyl-2,8-dioxabicyclo[3.2.1]octan-3-yl]-7,9-dihydroxy-2,6,8-trimethylundeca-2,4-dienamide

C22H37NO5 (395.26715920000004)


   
   

N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide

N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide

C26H37NO2 (395.2824142)


   

5-(3-Methyl-5-pentylfuran-2-yl)pentanoylcarnitine

5-(3-Methyl-5-pentylfuran-2-yl)pentanoylcarnitine

C22H37NO5 (395.26715920000004)


   

7-(3-Methyl-5-propylfuran-2-yl)heptanoylcarnitine

7-(3-Methyl-5-propylfuran-2-yl)heptanoylcarnitine

C22H37NO5 (395.26715920000004)


   

Tetradeca-5,7,9-trienedioylcarnitine

Tetradeca-5,7,9-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

Tetradeca-5,8,11-trienedioylcarnitine

Tetradeca-5,8,11-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

Tetradeca-7,9,11-trienedioylcarnitine

Tetradeca-7,9,11-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

Tetradeca-6,8,10-trienedioylcarnitine

Tetradeca-6,8,10-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

Tetradeca-4,7,10-trienedioylcarnitine

Tetradeca-4,7,10-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

Tetradeca-6,9,12-trienedioylcarnitine

Tetradeca-6,9,12-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

Tetradeca-8,10,12-trienedioylcarnitine

Tetradeca-8,10,12-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

(2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine

(2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine

C21H33NO6 (395.23077580000006)


   

Calix[5]pyrrole

Calix[5]pyrrole

C25H25N5 (395.210985)


   

1-(4-Cyclohexylphenoxy)-3-[4-(pyridin-2-yl)piperazin-1-yl]propan-2-ol

1-(4-Cyclohexylphenoxy)-3-[4-(pyridin-2-yl)piperazin-1-yl]propan-2-ol

C24H33N3O2 (395.25726380000003)


   

(5R)-5-tert-butyl-1-[(3S)-3-phenyl-3-(phenylthio)propyl]-2-azepanone

(5R)-5-tert-butyl-1-[(3S)-3-phenyl-3-(phenylthio)propyl]-2-azepanone

C25H33NOS (395.22827280000007)


   

4-(Diethylamino)benzoic acid [2-oxo-2-(4-phenyl-1-piperazinyl)ethyl] ester

4-(Diethylamino)benzoic acid [2-oxo-2-(4-phenyl-1-piperazinyl)ethyl] ester

C23H29N3O3 (395.22088040000006)


   
   

N-[(4-tert-butylphenyl)methyl]-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine

N-[(4-tert-butylphenyl)methyl]-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine

C25H25N5 (395.210985)


   

1-[[3-(3-Fluorophenyl)-1-(4-methoxyphenyl)-4-pyrazolyl]methyl]-4-methoxypiperidine

1-[[3-(3-Fluorophenyl)-1-(4-methoxyphenyl)-4-pyrazolyl]methyl]-4-methoxypiperidine

C23H26FN3O2 (395.2008948)


   

N-(9Z-octadecenoyl)-L-asparagine

N-(9Z-octadecenoyl)-L-asparagine

C22H39N2O4- (395.2909674)


   
   

(5Z)-5-(2-methylpropylidene)-3-[(2E,6R,8E,10E,12E)-6,8,10,12-tetramethyltetradeca-2,8,10,12-tetraenoyl]-2,5-dihydro-1H-pyrrol-2-one

(5Z)-5-(2-methylpropylidene)-3-[(2E,6R,8E,10E,12E)-6,8,10,12-tetramethyltetradeca-2,8,10,12-tetraenoyl]-2,5-dihydro-1H-pyrrol-2-one

C26H37NO2 (395.2824142)


   

4-[4-[(1S,5R)-3-[(2-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

4-[4-[(1S,5R)-3-[(2-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

C26H25N3O (395.199752)


   

(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C23H29N3O3 (395.22088040000006)


   

(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C23H29N3O3 (395.22088040000006)


   

(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C23H29N3O3 (395.22088040000006)


   

N-(2-hydroxyphenyl)-N-[(E)-[(3S,4R,5R)-3,4,5-trihydroxyhexylidene]amino]heptanediamide

N-(2-hydroxyphenyl)-N-[(E)-[(3S,4R,5R)-3,4,5-trihydroxyhexylidene]amino]heptanediamide

C19H29N3O6 (395.20562540000003)


   

(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C23H29N3O3 (395.22088040000006)


   

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2S,3R,6S)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

N-[(2S,3R,6S)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

C20H30FN3O4 (395.2220232)


   

N-[(2S,3S,6S)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

N-[(2S,3S,6S)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

C20H30FN3O4 (395.2220232)


   

N-[(2R,3R,6S)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

N-[(2R,3R,6S)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

C20H30FN3O4 (395.2220232)


   

N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

(2R,3R,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

(2R,3R,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

C23H29N3O3 (395.22088040000006)


   

(2S,3S,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

(2S,3S,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

C23H29N3O3 (395.22088040000006)


   

(2R,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

(2R,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

C23H29N3O3 (395.22088040000006)


   

N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

N-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-(4-phenylphenyl)-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide

N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-(4-phenylphenyl)-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide

C23H29N3O3 (395.22088040000006)


   

(1R,2aS,8bS)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

(1R,2aS,8bS)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

C23H29N3O3 (395.22088040000006)


   

3-[4-[(1R,5S)-6-[(2-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

3-[4-[(1R,5S)-6-[(2-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

C26H25N3O (395.199752)


   

[(1R)-1-[(4-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol

[(1R)-1-[(4-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol

C23H26FN3O2 (395.2008948)


   

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[3-(4-morpholinyl)propylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide

C20H33N3O5 (395.24200880000006)


   

N-[(2R,3S,6R)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

N-[(2R,3S,6R)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

C20H30FN3O4 (395.2220232)


   

N-[(2R,3R,6R)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

N-[(2R,3R,6R)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

C20H30FN3O4 (395.2220232)


   

N-[(2S,3S,6R)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

N-[(2S,3S,6R)-6-[2-[3-(dimethylamino)propylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-fluorobenzamide

C20H30FN3O4 (395.2220232)


   

N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide

C20H33N3O5 (395.24200880000006)


   

(2S,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

(2S,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

C23H29N3O3 (395.22088040000006)


   

(2S,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

(2S,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

C23H29N3O3 (395.22088040000006)


   

(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

C23H29N3O3 (395.22088040000006)


   

(2R,3S,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

(2R,3S,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[2-(4-morpholinyl)-1-oxoethyl]-2-azetidinecarbonitrile

C23H29N3O3 (395.22088040000006)


   

N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2R,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

N-[[(2R,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2S,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

N-[[(2S,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2R,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

N-[[(2R,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methylpropyl)-2-pyridinecarboxamide

C23H29N3O3 (395.22088040000006)


   

(2S,3R,4R)-2-[[benzoyl(methyl)amino]methyl]-4-(hydroxymethyl)-3-phenyl-N-propan-2-yl-1-azetidinecarboxamide

(2S,3R,4R)-2-[[benzoyl(methyl)amino]methyl]-4-(hydroxymethyl)-3-phenyl-N-propan-2-yl-1-azetidinecarboxamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-(4-phenylphenyl)-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide

N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-(4-phenylphenyl)-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide

C23H29N3O3 (395.22088040000006)


   

N-[[(2R,3R,4R)-4-(hydroxymethyl)-3-(4-phenylphenyl)-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide

N-[[(2R,3R,4R)-4-(hydroxymethyl)-3-(4-phenylphenyl)-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide

C23H29N3O3 (395.22088040000006)


   

1-[[(2S,3R,4R)-1-benzoyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-methyl-3-propylurea

1-[[(2S,3R,4R)-1-benzoyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-methyl-3-propylurea

C23H29N3O3 (395.22088040000006)


   

1-[[(2R,3S,4S)-1-benzoyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-methyl-3-propylurea

1-[[(2R,3S,4S)-1-benzoyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-methyl-3-propylurea

C23H29N3O3 (395.22088040000006)


   

(1R,2aR,8bR)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

(1R,2aR,8bR)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

C23H29N3O3 (395.22088040000006)


   

(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

C23H29N3O3 (395.22088040000006)


   

(1S,2aR,8bR)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

(1S,2aR,8bR)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

C23H29N3O3 (395.22088040000006)


   

cyclopropyl-[(8R,9S,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

cyclopropyl-[(8R,9S,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

C24H33N3O2 (395.25726380000003)


   

cyclopropyl-[(8S,9S,10S)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

cyclopropyl-[(8S,9S,10S)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

C24H33N3O2 (395.25726380000003)


   

cyclopropyl-[(8S,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

cyclopropyl-[(8S,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

C24H33N3O2 (395.25726380000003)


   

cyclopropyl-[(8R,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

cyclopropyl-[(8R,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

C24H33N3O2 (395.25726380000003)


   

4-[4-[(1R,5S)-6-[(3-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

4-[4-[(1R,5S)-6-[(3-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

C26H25N3O (395.199752)


   

1-[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-pyridin-4-ylethanone

1-[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-2-pyridin-4-ylethanone

C26H25N3O (395.199752)


   

3-[4-[(1S,5R)-3-[(2-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

3-[4-[(1S,5R)-3-[(2-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

C26H25N3O (395.199752)


   

[(1R)-1-[(2-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol

[(1R)-1-[(2-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol

C23H26FN3O2 (395.2008948)


   

N-(2-aminoethyl)-4,6-dinitro-N-(2,2,6,6-tetramethyl-1-oxido-piperidin-4-yl)benzene-1,3-diamine

N-(2-aminoethyl)-4,6-dinitro-N-(2,2,6,6-tetramethyl-1-oxido-piperidin-4-yl)benzene-1,3-diamine

C17H27N6O5 (395.2042832)


   

1-[(3R,3aR)-3-[(1S)-1-hydroxy-2-phenylethyl]-3,3a,6,7-tetrahydro-1H-cyclohepta[c]pyrrol-2-yl]-1-cyclohexanecarboxylic acid methyl ester

1-[(3R,3aR)-3-[(1S)-1-hydroxy-2-phenylethyl]-3,3a,6,7-tetrahydro-1H-cyclohepta[c]pyrrol-2-yl]-1-cyclohexanecarboxylic acid methyl ester

C25H33NO3 (395.2460308000001)


   

5-aminopentyl 3-O-(beta-L-rhamnopyranosyl)-beta-D-glucopyranoside

5-aminopentyl 3-O-(beta-L-rhamnopyranosyl)-beta-D-glucopyranoside

C17H33NO9 (395.21552080000004)


   

5-aminopentyl alpha-L-rhamnopyranosyl-(1->3)-alpha-L-rhamnopyranoside

5-aminopentyl alpha-L-rhamnopyranosyl-(1->3)-alpha-L-rhamnopyranoside

C17H33NO9 (395.21552080000004)


   

1-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)ethyl]-4-(4-fluorobenzoyl)piperidinium

1-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-1-yl)ethyl]-4-(4-fluorobenzoyl)piperidinium

C24H28FN2O2+ (395.21347)


   

[(2R)-2-amino-3-hexadecoxypropyl] dihydrogen phosphate

[(2R)-2-amino-3-hexadecoxypropyl] dihydrogen phosphate

C19H42NO5P (395.2800452000001)


   

2-aminoethyl [2-hydroxy-3-[(Z)-tridec-9-enoxy]propyl] hydrogen phosphate

2-aminoethyl [2-hydroxy-3-[(Z)-tridec-9-enoxy]propyl] hydrogen phosphate

C18H38NO6P (395.24366180000004)


   
   

alpha-(4-Dimethylaminophenyl)-omega-(9-phenanthryl)heptane

alpha-(4-Dimethylaminophenyl)-omega-(9-phenanthryl)heptane

C29H33N (395.26128580000005)


   

2-[[(E)-2-acetamido-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-acetamido-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C17H36N2O6P+ (395.2310866)


   

2-[[(E)-2-(butanoylamino)-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-(butanoylamino)-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C17H36N2O6P+ (395.2310866)


   

2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C17H36N2O6P+ (395.2310866)


   

3-farnesyl-3-hydroxy-2-methyl-1-oxo-1lambda(5)-quinolin-4-one

3-farnesyl-3-hydroxy-2-methyl-1-oxo-1lambda(5)-quinolin-4-one

C25H33NO3 (395.2460308000001)


A member of the class of quinoline N-oxides that is 3-hydroxy-2-methyl-1-oxo-1lambda(5)-quinolin-4-one carrying an additional (2E,6E)-farnesyl group at position 3.

   
   

N-Tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide

N-Tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide

C24H33N3O2 (395.25726380000003)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

   

(5Z)-7-[(1R,2R,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]-N-(2-hydroxyethyl)hept-5-enamide

(5Z)-7-[(1R,2R,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]-N-(2-hydroxyethyl)hept-5-enamide

C22H37NO5 (395.26715920000004)


   

Sphingosine 1-phosphate (d19:1-P)

Sphingosine 1-phosphate (d19:1-P)

C19H42NO5P (395.2800452000001)


   
   

1-(9E-decenyl)-sn-glycero-3-phosphocholine

1-(9E-decenyl)-sn-glycero-3-phosphocholine

C18H38NO6P (395.24366180000004)


   

aurachin A

aurachin A

C25H33NO3 (395.2460308000001)


An A-type aurichin that is 1,2-dihydrofuro[2,3-c]quinoline 5-oxide which is substituted at position 2 by a (6E)-10-hydroxy-2,6-dimethylundeca-2,6-dien-10-yl group and at position 4 by a methyl group (relative configuration shown). Found in the myxobacterium Stigmatella aurantiaca strain Sg a15.

   
   
   
   

NA-Histamine 20:5(5Z,8Z,11Z,14Z,17Z)

NA-Histamine 20:5(5Z,8Z,11Z,14Z,17Z)

C25H37N3O (395.2936472)


   
   
   
   
   
   

(1r,4s,7s,9r)-16-acetyl-6-hydroxy-4-isopropyl-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

(1r,4s,7s,9r)-16-acetyl-6-hydroxy-4-isopropyl-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C23H29N3O3 (395.22088040000006)


   

(1s,12s,13r,14r,15e,17r)-13-(ethoxycarbonyl)-15-ethylidene-5-methoxy-3,17-dimethyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-17-ium

(1s,12s,13r,14r,15e,17r)-13-(ethoxycarbonyl)-15-ethylidene-5-methoxy-3,17-dimethyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-17-ium

[C24H31N2O3]+ (395.23345559999996)


   

n-(3-{[3-({3-[(4-aminobutyl)amino]propyl}amino)propyl](hydroxy)amino}propyl)-4-hydroxybenzamide

n-(3-{[3-({3-[(4-aminobutyl)amino]propyl}amino)propyl](hydroxy)amino}propyl)-4-hydroxybenzamide

C20H37N5O3 (395.28962520000005)


   

n-{15-acetyl-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-14-en-6-yl}-n-methylacetamide

n-{15-acetyl-12,16-dimethyl-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-14-en-6-yl}-n-methylacetamide

C26H37NO2 (395.2824142)


   

[(2r,3r,4s,6e)-2-amino-1,3-dihydroxyoctadec-6-en-4-yl]oxysulfonic acid

[(2r,3r,4s,6e)-2-amino-1,3-dihydroxyoctadec-6-en-4-yl]oxysulfonic acid

C18H37NO6S (395.23414620000005)


   

(1r,7ar)-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2,3-dimethylbut-2-enoate

(1r,7ar)-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2,3-dimethylbut-2-enoate

C21H33NO6 (395.23077580000006)


   

(13r)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]tridecane-1,2,7,9,13-pentol

(13r)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]tridecane-1,2,7,9,13-pentol

C18H37NO8 (395.2519042)


   

5-[(8as)-6-(3,4-dimethoxyphenyl)-8a-methyl-2,3,5,8-tetrahydro-1h-indolizin-7-yl]-2-methoxyphenol

5-[(8as)-6-(3,4-dimethoxyphenyl)-8a-methyl-2,3,5,8-tetrahydro-1h-indolizin-7-yl]-2-methoxyphenol

C24H29NO4 (395.20964740000005)


   

n-(4-{[3-({3-[(3-aminopropyl)amino]propyl}amino)propyl]amino}butyl)-2,5-dihydroxybenzenecarboximidic acid

n-(4-{[3-({3-[(3-aminopropyl)amino]propyl}amino)propyl]amino}butyl)-2,5-dihydroxybenzenecarboximidic acid

C20H37N5O3 (395.28962520000005)